



**SCdU CMID – NEFROLOGIA E DIALISI**

Center of Excellence of Nephrologic, Rheumatologic and Rare Diseases  
Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley  
San Giovanni Bosco Hub Hospital and Department of Clinical and Biological Sciences  
University of Turin

Director: *Prof. Dario Roccatello*

**HYBRID EVENT**

**25<sup>TH</sup> CONGRESS ON**

# **IMMUNE PATHOLOGY AND ORPHAN DISEASES**

**Celebrating quarter century of activity**

**Spazio Eventi "La Centrale"**

**Via Bologna - Torino**

**TURIN**

**JANUARY 27<sup>TH</sup> – 29<sup>TH</sup>, 2022**

## INVITED SPEAKERS

Aiuti Alessandro  
Baldovino Simone  
Bianchi Gerolamo  
Cuadrado Maria  
Di Fonzo Alessio  
Di Rocco Maia  
De Simone Emanuele  
Fenoglio Roberta  
Galeazzi Mauro  
Gerli Roberto  
Glassock Richard  
Houssuau Frederic  
Jayne David  
Little Mark  
Moroni Gabriella  
Massara Carlo  
Matucci Cerinic Marco  
Montini Giovanni  
Pani Antonello  
Pozzato Marco  
Roccatello Dario  
Rossi Daniela  
Sarzi Puttini Piercarlo  
Sciascia Savino  
Shoenfeld Yehuda  
Spada Marco

## CMID SECRETARIAT

Rita Maria Bianco: Mobile 328 8863484

## ORGANIZING SECRETARIAT



**sylene**  
eventi & congressi

Via G. Medici 23 – 10143 Turin (Italy)  
Phone +39 0117499601  
E-mail: [patologiaimmune@seleneweb.com](mailto:patologiaimmune@seleneweb.com)  
Website: [www.selenecongressi.it](http://www.selenecongressi.it)

**THURSDAY (02:00 P.M. – 06:30 P.M.)**

**PECULIAR ISSUES IN RARE DISEASES**

Long term enzyme replacement therapy for Fabry disease: cost-benefit ratio

Gaucher diseases: Relations with Parkinson's disease

Gene therapy in rare diseases

RNA-based therapeutics from antisense oligonucleotides to RNA

inhibitors: the cases of TTR amyloidosis and primary hyperoxaluria

New therapies of metabolic neurodegenerative diseases: the example of alpha mannosidosis

**FRIDAY (08:30 A.M. – 01:30 P.M.)**

**EMERGING RHEUMATOLOGIC ISSUES**

Biomarkers and individualized therapeutic approaches in Rheumatoid Arthritis

Special therapeutic approaches in Rheumatoid Arthritis

What should drive treatment of spondyloarthritis

How to manage psoriatic arthritis

Biologics and small molecules in rheumatology: effects in comparison

The antifibrotic therapeutic approach in immune-mediated diseases

COVID19-SARS vaccination and autoimmunity

**FRIDAY (02:30 P.M. – 06:30 P.M.)**

**EMERGING RHEUMATOLOGIC AND NEPHROLOGIC ISSUES**

Renal involvement in Sjogren's syndrome

ANCA vasculitis: new therapeutic trends

ANCA vasculitis: suggested treatment for the refractory forms

Target therapy in Systemic Lupus Erythematosus

What did we learn from anti-BAFF therapy in Lupus Nephritis

Discontinuation therapy in Lupus Nephritis

**SATURDAY (08:30 A.M. – 01:30 P.M.)**

**EMERGING NEPHROLOGIC ISSUES**

Refractory Lupus Nephritis

Anti-complement therapy in thrombotic microangiopathy and in glomerulonephritis: where are we going

Future trends in the therapy of Lupus Nephritis

Aging and renal diseases

Green dialysis: the needed itinerary